➖ Neutral🌐 Global
Agois acquires $165M blood disorder therapy from Korea's Oscotec after Phase 2 failure
Agios Pharmaceuticals (AGIO), Oscotec (비공개 비상장 기업)·FierceBiotech·June 2, 2026
ClinicalFinanceCorporate
Total: 165MUpfront: 165MMilestone: null
AI Generated (Flux.1-schnell)
✨AI SummaryAI
Key Takeaways: Agois Pharmaceuticals acquired a blood disorder therapeutic candidate from privately held Korean company Oscotec for $165 million shortly after the asset failed to meet its primary endpoints in Phase 2. The transaction can be viewed as a strategic investment aimed at diversifying Agois’s pipeline. Although the candidate did not achieve its Phase 2 objectives, the company is evaluating opportunities for further development. This move signals Agois’s intent to strengthen its position in the blood disorder market.
💬Why It Matters
The deal enables Agois to rapidly expand its pipeline, enhancing revenue growth potential and increasing its appeal to investors. Acquisitions that reposition assets are critical for mitigating the risk associated with new‑drug development failures.